Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

Conclusions: Patients with RAS/BRAF/PIK3CA wild-type mCRC had a sufficient RR following first-line treatment with CapeOX + cetuximab. These results suggest that this combination therapy should be considered as a treatment option for patients with advanced mCRC.

Source: Journal of Cancer - December 14, 2018 Category: Cancer & Oncology Authors: Shigeyoshi Iwamoto, Hiromichi Maeda, Shoichi Hazama, Koji Oba, Naoko Okayama, Yutaka Suehiro, Takahiro Yamasaki, Nobuaki Suzuki, Hiroaki Nagano, Junichi Sakamoto, Hideyuki Mishima, Naoki Nagata Tags: Research Paper Source Type: research